Skip Navigation

European Heart Journal 2000 21(21):1767-1775; doi:10.1053/euhj.1999.2041
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Meneveau, N
Right arrow Articles by Bassand, J.P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meneveau, N
Right arrow Articles by Bassand, J.P
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS Trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study

N Meneveaua, F Schielea, G Grollierb, B Farahc, J.M Lablanched, K Khalifée, J Machecourtf, N Danching, J.E Wolfh, M Simpsoni, J.B Hakj and J.P Bassanda,f1

a Hôpital Jean-Minjoz, Besançon
b Hôpital de la Côte de Nacre, Caen
c Hôpital Universitaire Tenon, Paris
d Hôpital Cardiologique, Lille
e Hôpital régional de Metz
f Hôpital de la Tronche, Grenoble
g Hôpital Universitaire Brabois, Nancy
h Hôpital du Bocage, Dijon
i Cordis, Miami Lakes, Florida, U.S.A.
j Cordis, Waterloo, Belgium

revised November 29, 1999; accepted December 1, 1999

Abstract

Background We hypothesized that intramural delivery of nadroparin, a low molecular weight heparin, would prevent in-stent restenosis by inhibiting neointimal hyperplasia in an angioplasty model free of arterial remodelling.

Methods and Results In a prospective randomized multicentre trial, 250 patients submitted to balloon angioplasty followed by stent implantation were randomized into control group (no local drug delivery) or intramural delivery of nadroparin (2ml of 2500 anti-Xa-units.ml–1with a microporous catheter). An ancillary intravascular ultrasound substudy was performed to supplement angiographic data with specific measurements of in-stent neointimal hyperplasia. The primary end-point was the late loss in minimal luminal diameter on the 6 month follow-up angiogram. Secondary end-points included feasibility and safety of local nadroparin delivery, and major adverse cardiac events at 8 weeks and 6 months follow-up. Local delivery of nadroparin was successful in 124 patients (99·2% success rate) and was not associated with an increase in stent thrombosis, coronary artery dissection, side branch occlusion, distal embolization or abrupt arterial closure. At angiographic follow-up, the late loss in lumen diameter was 0·84±0·62mm in the control group compared to 0·88±0·63mm in the nadroparin group (P=0·56). Angiographic restenosis rate (defined as a >50% diameter stenosis) did not differ in the control group (20%) compared to the nadroparin group (24%). The average area of neointimal tissue within the stent was 2·86±0·64mm2vs 2·90±0·53mm2(P=0·57), control vs nadroparin groups. There was no difference in major adverse cardiac events at any time (88·8% vs 89·6% event free survival at 6 months, control vs nadroparin).

Conclusion Intramural delivery of nadroparin with a microporous catheter after stent deployment was feasible and safe but had no effect in reducing restenosis or the occurrence of major adverse clinical events over 6 months.

Key Words: Restenosis, stents, heparin

f1 Correspondence: Jean-Pierre Bassand, MD, FESC, FACC, Department of Cardiology, Pôle Coeur Poumon, CHU Jean-Minjoz, 25030 Besançon Cedex, France.

References

  1. Serruys P, De Jaegere P, Kiemenij F. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary heart disease. N Engl J Med. 1994;331:489–495[Abstract/Free Full Text]
  2. Fischman DL, Leon MB, Baim DS. A randomized comparison of coronary-stent placement and balloon angioplasty in treatment of coronary artery disease (STRESS trial). N Engl J Med. 1994;331:496–501[Abstract/Free Full Text]
  3. Hanke H, Oberhoff M, Hanke S. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular-weight heparin. Circulation. 1992;85:1548–1556[Abstract/Free Full Text]
  4. Karsch KR, Preisack MB, Baildon R. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE Trial). J Am Coll Cardiol. 1996;28:1437–1443[Abstract]
  5. Lablanche JM, McFadden EP, Meneveau N. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT Study. Circulation. 1997;96:3396–3402[Abstract/Free Full Text]
  6. Faxon DP, Spiro TE, Minor S. Low molecular weight heparin in prevention of restenosis after angioplasty: results of Enoxaparin Restenosis (ERA) Trial. Circulation. 1994;90:908–914[Abstract/Free Full Text]
  7. Oberhoff M, Herdeg C, Baumbach A. Time course of smooth muscle cell proliferation after local delivery of low-molecular-weight heparin using a porous balloon catheter. Cathet Cardiovasc Diagn. 1997;41:268–274[CrossRef][ISI][Medline]
  8. Serruys PW, van Hout B, Bonnier H. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998;352:673–681[CrossRef][ISI][Medline]
  9. Hoffmann R, Mintz GS, Pichard AD, Kent KM, Satler LF, Leon MB. Intimal hyperplasia thickness at follow-up is independent of stent size: a serial intravascular ultrasound study. Am J Cardiol. 1998;82:1168–1172[CrossRef][ISI][Medline]
  10. Mehran R, Mintz GS, Hong MK. Validation of the in vivo intravascular ultrasound measurement of in-stent neointimal hyperplasia volumes. J Am Coll Cardiol. 1998;32:794–799[Abstract/Free Full Text]
  11. Herbert JM, Maffrand JP. Heparin interactions with cultured human vascular endothelial and smooth muscle cells: incidence on vascular smooth muscle cell proliferation. J Cell Physiol. 1989;138:424–432[CrossRef][ISI][Medline]
  12. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977;265:625–626[CrossRef][Medline]
  13. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury: IV. Heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res. 1986;58:839–845[Abstract/Free Full Text]
  14. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury: II. Inhibition of smooth muscle cell growth by heparin. Lab Invest. 1985;52:611–616[ISI][Medline]
  15. Guyton J, Rosenberg R, Clowes A, Karnowsky M. Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res. 1980;46:625–634[Free Full Text]
  16. Castellot JJ Jr, Addonozio ML, Rosenberg R, Karnowsky MJ. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J Cell Biol. 1981;90:372–377[Abstract/Free Full Text]
  17. Herbert JM, Malffrand JP. Heparin interactions with cultured human vascular endothelial and smooth muscle cells: Incidence on vascular smooth muscle cell proliferation. J Cell Physiol. 1989;138:424–432[CrossRef][ISI][Medline]
  18. Herrmann JPR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: The search for the Holy Grail? (part II). Drugs. 1993;46:249–262[ISI][Medline]
  19. Herrmann JPR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: The search for the Holy Grail? (part I). Drugs. 1993;46:18–52[ISI][Medline]
  20. Kiesz RS, Buszman P, Martin JL. Polish-american local lovenox nir stent assessment study (POLONIA): final results (Abstr). J Am Coll Cardiol. 1999;33:1007–1085
  21. Chan P, Patel M, Betteridge L. Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. Lancet. 1993;341:341–342[CrossRef][ISI][Medline]
  22. Gradus-Pizzlo I, Wilensky RL, March KL. Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: effects on restenosis and implications for catheter-base drug delivery. J Am Coll Cardiol. 1995;26:1549–1557[Abstract]
  23. Camenzind E, Bakker WH, Reijs A. Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. Circulation. 1997;96:154–165[Abstract/Free Full Text]
  24. Azrin MA, Mitchel JF, Fram DB. Decreased platelet deposition and smooth muscle cell proliferation after intramural heparin delivery with hydrogel-coated balloons. Circulation. 1994;90:433–441[Abstract/Free Full Text]
  25. Wilenský RL, March KL, Gradus-Pizlo I. Regional and arterial localization of radioactive microparticles following local delivery using unsupported and supported porous balloon catheters. Am Heart J. 1995;129:852–859[CrossRef][ISI][Medline]
  26. Hong MK, Wong SC, Farb A. Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery. Coronary Artery Dis. 1993;4:1023–1027[ISI][Medline]
  27. Muller DWM, Topol EJ, Abrams GD, Gallagher KP, Ellis SG. Intramural methotrexate therapy for the prevention of neointimal thickening after balloon angioplasty. J Am Coll Cardiol. 1992;20:460–466[Abstract]
  28. Lambert CR, Rowland S. Fluid dynamics of catheter delivery: effects on delivery efficiency and localisation. March KL. Gene transfer in the cardiovascular system: experimental approaches and therapeutic implications. Boston: Kluwer Academic Publishers; 1997. p. 201–217
  29. Rome JJ, Shayani V, Flugelman MY. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall: modeling with microscopictracer particles and verification with a recombinant adenoviral vector. Arterioscler Thromb. 1994;14:148–161[Abstract/Free Full Text]
  30. Camenzind E, Kint PK, Di Mario C. Intracoronary heparin delivery in humans: acute feasibility and long-term results. Circulation. 1995;92:2463–2472[Abstract/Free Full Text]
  31. Wilensky RL, March KL, Hathaway DR. Direct intraarterial wall injection of microparticles via a catheter: A potential drug delivery strategy following angioplasty. Am Heart J. 1991;122:1136–1140[CrossRef][ISI][Medline]
  32. Hong MJ, Bhatti T, Matthews BJ. The effect of porous infusion balloon-delivered angiopeptin on myointimal hyperplasia after ballon injury in the rabbit. Circulation. 1993;88:638–648[Abstract/Free Full Text]
  33. Lambert T, Dev V, Recharia I, Forrester JS, Litvak F, Eigler NL. Localized arterial wall drug delivery from a polymer-coated removable metallic stent. Kinetics of distribution and bioactivity of forskolin. Circulation. 1994;90:1003–1011[Abstract/Free Full Text]
  34. Nasser TK, Wilensky RL, Mehdi K, March KL. Microparticle deposition in periarterial microvasculature and intramural dissections following porous balloon delivery into atherosclerotic vessels. Quantitation and localization by confocal scanning laser microscopy. Am Heart J. 1996;131:892–898[CrossRef][ISI][Medline]
  35. Fernandez-Ortiz A, Meyer BJ, Mailhac A. Intravascular local delivery: an iontophoretic approach. Circulation. 1994;89:1518–1522[Abstract/Free Full Text]
  36. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol. 1992;19:418–432[Abstract]
  37. Schwartz RS, Huber KC, Murphy JG. Restenosis and the proportional neointimal response to coronary injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267–274[Abstract]
  38. Stadius ML, Collins C, Kernoff R. Local infusion balloon angioplasty to obviate restenosis compared with conventional balloon angioplasty in an experimental model of atherosclerosis. Am Heart J. 1993;126:47–56[ISI][Medline]
  39. Rasheed Q, Cacchione JG, Berry J. Local intramural drug delivery using an infusion balloon following angioplasty in normal and atherosclerotic vessels. Cath Cardiovasc Diag. 1994;31:240–245[ISI][Medline]
  40. Plante S, Dupuis G, Mongeau CJ, Durand P. Porous balloon catheters for local delivery: assessment of vascular damage in a rabbit iliac angioplasty model. J Am Coll Cardiol. 1994;24:820–824[Abstract]
  41. Lambert CR, Leone JE, Rowland SM. Local drug delivery catheters: functional comparison of porous and microporous designs. Coronary Artery Dis. 1993;4:469–475[ISI][Medline]
  42. Höfling B, Huehns TY. Intravascular local drug delivery after angioplasty. Eur Heart J. 1995;16:437–440[Free Full Text]
  43. Pavlides GS, Barath P, Maginas A, Vasilikos V, Cokkinos DV, O'Neil WW. Intramural drug delivery by direct injection within the arterial wall:first clinical experience with a novel intracoronary delivery-infiltrator system. Cathet Cardiovasc Diagn. 1997;41:287–292[CrossRef][ISI][Medline]
  44. Barath P, Popov A, Dillehay GL, Matos G, McKiernan T. Infiltrator angioplasty balloon catheter: a device for combined angioplasty and intramural site-specific treatment. Cathet Cardiovasc Diagnos. 1997;41:333–341

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J CARDIOVASC PHARMACOL THERHome page
N. F. Meneveau, B. D. Klugherz, B. Chaquor, M. A. Golden, M. M. Jouille, E. Macarek, P. B. Weisz, and R. L. Wilensky
Separate and Combined Effects of Local and Continuous Intravenous Administration of {beta}-Cyclodextrin Tetradecasulfate on Intimal Hyperplasia after Angioplasty in Porcine Coronary Arteries
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 53 - 60.
[Abstract] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
B. M. Sasseen, B. D. Gray, D. Gal, R. Lorinc, D. C. Carpenter, B. D. Klugherz, and R. L. Wilensky
Local Delivery of a Hydrophobic Heparin Reduces Neointimal Hyperplasia After Balloon Injury in Rat Carotid but not Pig Coronary Arteries
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 377 - 383.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
P. Widimsky
Intracoronary drug delivery: mechanically too rough, pharmacologically too weak?
Eur. Heart J., November 1, 2000; 21(21): 1729 - 1730.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Meneveau, N
Right arrow Articles by Bassand, J.P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meneveau, N
Right arrow Articles by Bassand, J.P
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?